These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High dose dexamethasone as first line therapy of multiple myeloma? A case report. Meregalli M; Bertola G; Grando D Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388 [TBL] [Abstract][Full Text] [Related]
3. Gastric invasion of multiple myeloma presenting as gastrointestinal bleeding. Nakajima K; Sueki Y; Koshiishi M; Kawashima I; Nozaki Y; Mitsumori T; Kirito K Int J Hematol; 2015 Jun; 101(6):525-6. PubMed ID: 25916464 [No Abstract] [Full Text] [Related]
4. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol]. Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860 [No Abstract] [Full Text] [Related]
6. An unusual case of pulmonary hypertension in a young male. Rostagno C; Ciolli S; Prisco D Intern Emerg Med; 2006; 1(2):127-32. PubMed ID: 17111785 [No Abstract] [Full Text] [Related]
7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
10. VAD followed by VMCP: an alternative regimen for multiple myeloma. Wadhwa J; Kumar L; Kochupillai V Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477 [TBL] [Abstract][Full Text] [Related]
11. The treatment of multiple myeloma. Alexanian R; Dimopoulos M N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856 [No Abstract] [Full Text] [Related]
12. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Hussein MA Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227 [TBL] [Abstract][Full Text] [Related]
13. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Ross DM; To LB; Horvath N Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273 [TBL] [Abstract][Full Text] [Related]
15. [IgD myeloma manifesting as acute renal insufficiency]. Duvic C; Sarret D; De Revel T; Hérody M; Didelot F; Labaye J; Nédélec G Rev Med Interne; 2000 Sep; 21(9):799-803. PubMed ID: 11039177 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507 [TBL] [Abstract][Full Text] [Related]
17. Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma. Shah S; Cavenagh J; Sheaf M; Thuraisingham RC Am J Kidney Dis; 2004 Feb; 43(2):e10-2. PubMed ID: 14750118 [TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: biology and therapy. Barlogie B; Epstein J J Cancer Res Clin Oncol; 1990; 116(1):109-11. PubMed ID: 2312600 [No Abstract] [Full Text] [Related]
19. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? Dimopoulos MA; Kastritis E Leuk Lymphoma; 2006 Nov; 47(11):2271-2. PubMed ID: 17107895 [No Abstract] [Full Text] [Related]
20. Bilateral transient hearing loss associated with vincristine therapy: case report. Aydogdu I; Ozturan O; Kuku I; Kaya E; Sevinc A; Yildiz R J Chemother; 2000 Dec; 12(6):530-2. PubMed ID: 11154039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]